Equities analysts expect Henry Schein, Inc. (NASDAQ:HSIC) to announce sales of $2.93 billion for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Henry Schein’s earnings, with estimates ranging from $2.83 billion to $3.01 billion. Henry Schein posted sales of $2.84 billion in the same quarter last year, which would indicate a positive year over year growth rate of 3.2%. The business is expected to announce its next earnings results on Monday, November 1st.
According to Zacks, analysts expect that Henry Schein will report full year sales of $11.94 billion for the current fiscal year, with estimates ranging from $11.64 billion to $12.18 billion. For the next fiscal year, analysts forecast that the firm will post sales of $12.34 billion, with estimates ranging from $11.89 billion to $12.95 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Henry Schein.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 3rd. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.13. The company had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.87 billion. Henry Schein had a return on equity of 15.86% and a net margin of 5.09%. The firm’s revenue for the quarter was up 76.2% on a year-over-year basis.
Large investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC increased its stake in Henry Schein by 3.0% in the second quarter. Parametric Portfolio Associates LLC now owns 431,320 shares of the company’s stock worth $32,000,000 after purchasing an additional 12,654 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Henry Schein in the second quarter worth $701,000. Marshall Wace LLP increased its stake in Henry Schein by 2.4% in the second quarter. Marshall Wace LLP now owns 104,241 shares of the company’s stock worth $7,734,000 after purchasing an additional 2,463 shares during the period. Boston Common Asset Management LLC grew its position in shares of Henry Schein by 111.8% during the 2nd quarter. Boston Common Asset Management LLC now owns 106,460 shares of the company’s stock worth $7,898,000 after buying an additional 56,185 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Henry Schein by 5.4% during the 2nd quarter. Wells Fargo & Company MN now owns 675,697 shares of the company’s stock worth $50,130,000 after buying an additional 34,374 shares in the last quarter. Institutional investors own 93.16% of the company’s stock.
Shares of NASDAQ:HSIC traded up $0.73 during mid-day trading on Tuesday, reaching $78.44. 624,707 shares of the company traded hands, compared to its average volume of 907,888. The company’s 50 day moving average price is $76.93 and its 200-day moving average price is $74.39. The firm has a market cap of $10.96 billion, a PE ratio of 18.46, a PEG ratio of 1.32 and a beta of 0.88. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.79 and a quick ratio of 0.98. Henry Schein has a 52 week low of $56.31 and a 52 week high of $83.45.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Further Reading: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.